MoonLake Immunotherapeutics

MLTX · NASDAQ · Healthcare / Biotechnology

12.50USD-0.37 (-2.87%)

Price History

Full chart

Market Stats

Previous Close12.87

Open12.86

Day Range12.39 – 13.11

52-Week Range6.56 – 23.29

Volume1.18M

Market Cap1.02B

P/E (TTM)0.00

Forward P/E0.00

EPS-3.84

Dividend Yield0.00%

Beta1.03

50-Day Avg15.94

200-Day Avg16.84

About

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Jorge Santos da Silva Ph.D.
Employees130
HeadquartersDorfstrasse 29, Zug, Switzerland, 6300, USA
Websitehttps://www.moonlaketx.com

Leadership

Dr. Jorge Santos da Silva Ph.D.Co-Founder, Interim Chair of the Board & CEO · b. 1977
Dr. Kristian Reich M.D., Ph.D.Co-Founder & Chief Scientific Officer · b. 1966
Mr. Matthias BodenstedtChief Financial Officer · b. 1988
Mr. Oliver Daltrop Ph.D.Chief Technical Officer
Ms. Carla BretesDirector of Investor Relations & External Communications
Mr. Nicolas Mosimann Ph.D.General Counsel
Joana CortezAssociate Vice-President of Legal & Compliance
Tino AnthamattenVice President of Marketing, Market Access & Pricing
Luciana MarquesAssociate Vice-President of HR, People and Culture
Ms. Nuala BrennanChief Clinical Development Officer

Financials

Income Statement

Currency: USD	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	-	-	0	0	0	0
Cost of Revenue	-	4.97K	12.36K	13.16K	1.38M	2.62M
Gross Profit	-	-4.97K	-12.36K	-13.16K	-1.38M	-2.62M
Operating Expense	-	4.57M	65.05M	54.11M	141.71M	242.22M
Operating Income	-105.75K	-4.57M	-65.06M	-54.12M	-143.09M	-244.83M
EBITDA	-90.84K	-4.57M	-65.05M	-43.61M	-119.58M	-219.85M
Net Income	-90.84K	-4.54M	-64.51M	-36.01M	-118.94M	-227.32M
R&D	-	35.52M	42.05M	31.80M	112.77M	202.86M
Interest Expense	-	0	591.73K	0	0	7.25M

Balance Sheet

Currency: USD	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	116.63M	9.68M	76.84M	526.54M	477.93M	424.43M
Total Liabilities	4.15M	21.33M	8.08M	13.05M	24.54M	119.95M
Total Equity	112.48M	-11.65M	48.90M	495.68M	446.82M	304.48M
Cash	1.34M	8.04M	39.51M	451.17M	180.43M	334.52M
Total Debt	58.06K	15.00M	282.58K	3.70M	2.83M	75.71M
Net Debt	-1.28M	6.96M	-39.22M	-447.47M	-177.60M	-258.81M

Cash Flow

Currency: USD	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-316.69K	-35.18M	-55.89M	-42.78M	-116.59M	-196.01M
Investing Cash Flow	-115.00M	-50.71K	-32.34M	-25.18M	-205.60M	202.99M
Financing Cash Flow	116.65M	43.26M	119.69M	479.70M	51.31M	146.00M
Capital Expenditure	0	50.71K	16.01K	284.00K	519.52K	35.00K
Free Cash Flow	-316.69K	-35.23M	-55.91M	-43.06M	-117.11M	-196.04M
Dividends Paid	-	51.92K	-	-	-	-
FCF to OCF	100.00%	100.14%	100.03%	100.66%	100.45%	100.02%
Dividend Paid to FCF	-	-0.15%	-	-	-	-

Earnings

Report Date	Dec 3, 2020	Mar 31, 2021	May 21, 2021	Aug 16, 2021	Nov 12, 2021	Feb 17, 2022	May 16, 2022	Aug 12, 2022	Nov 14, 2022	Mar 20, 2023	May 12, 2023	Aug 10, 2023	Nov 14, 2023	Feb 29, 2024	May 7, 2024	Aug 7, 2024	Nov 7, 2024	Feb 26, 2025	May 5, 2025	Aug 5, 2025	Nov 5, 2025	Feb 26, 2026	May 11, 2026	Aug 10, 2026	Nov 4, 2026
EPS Estimate	0.00	-	-	-	-	-	-0.35	-0.54	-0.34	-0.28	-0.31	-0.29	-0.25	-0.23	-0.21	-0.28	-0.45	-0.59	-0.74	-0.76	-0.89	-0.98	-0.92	-0.90	-0.77
EPS Actual	0.00	-0.01	-0.01	-0.01	-0.14	-0.15	-0.35	-0.34	-0.27	-0.43	-0.23	-0.23	-0.18	-0.12	-0.22	-0.39	-0.56	-0.72	-0.63	-0.87	-1.10	-0.92	-0.98	-0.84	-
Surprise	-	-	-	-	-	-	0.00%	37.04%	20.59%	-53.57%	25.81%	20.69%	28.00%	47.83%	-4.76%	-39.29%	-24.44%	-22.03%	14.34%	-14.47%	-23.60%	6.05%	-6.52%	6.67%	-
Timing	-	-	-	-	-	After-hours	After-hours	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	-	Pre-market	Pre-market	-

Key Statistics & Ratios

Market Cap1.02B

Enterprise Value662.38M

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book2.56

EPS-3.84

Book Value5.12

Revenue (TTM)0

Gross Profit (TTM)0

EBITDA-265.10M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-67.48%

Return on Assets-32.44%

Shares Outstanding85.11M

Shares Float55.47M

Beta1.03

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Strong Buy

Based on 16 analystsTarget 28.54

Strong Buy
12
Buy
4

Ownership Breakdown

Institutions: 87.78%
Insiders: 8.18%
Retail / Other: 4.04%

Top Institutional Holders

Bvf Inc
16.00M18.80%
Deep Track Capital, LP
7.00M8.22%
Cormorant Asset Management, LLC
4.48M5.26%
HHG PLC
3.45M4.06%
D. E. Shaw & Co LP
3.37M3.95%
Logos Global Management LP
2.67M3.14%
Citadel Advisors Llc
1.97M2.32%
Two Sigma Investments LLC
1.72M2.02%
Weiss Asset Management LP
1.71M2.01%
MPM Oncology Impact Management LP
1.61M1.89%
Vivo Capital, LLC
1.40M1.65%
Point72 Asset Management, L.P.
1.37M1.61%
T. Rowe Price Associates, Inc.
1.29M1.52%
The Goldman Sachs Group Inc
1.13M1.33%
JPMorgan Chase & Co
1.09M1.28%
Balyasny Asset Management LLC
1.07M1.25%
BlackRock Inc
1.02M1.20%
Great Point Partners LLC
855.81K1.01%

Top Fund Holders

Jupiter Merian Glb Eq Abs Rt I USD Acc
1.18M1.39%
T. Rowe Price Small-Cap Value
1.06M1.25%